We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+5.34%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.47B
AUM Growth
-$28.4M
Cap. Flow
-$57.4M
Cap. Flow %
-2.32%
Top 10 Hldgs %
69.94%
Holding
36
New
–
Increased
10
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$9.56M
2
IMMU
Immunomedics Inc
IMMU
+$4.98M
3
CELG
Celgene Corp
CELG
+$3.04M
4
FOLD
Amicus Therapeutics
FOLD
+$2.77M
5
INSM icon
Insmed
INSM
+$2.73M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$71.5M
2
ALGN icon
Align Technology
ALGN
+$13.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$319M 12.89%
708,917
-181,392
-20% -$71.5M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$13B
$247M 9.99%
2,549,431
– –
UTHR icon
3
United Therapeutics
UTHR
$22.5B
$208M 8.4%
1,625,234
– –
STAA icon
4
STAAR Surgical
STAA
$1.26B
$169M 6.83%
3,521,565
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$167M 6.74%
1,200,201
+13,774
+1% +$1.73M
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$153M 6.2%
5,221,026
+247,019
+5% +$9.56M
INSM icon
7
Insmed
INSM
$29.2B
$149M 6.01%
7,357,283
+120,700
+2% +$2.73M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$119M 4.8%
840,372
+7,836
+0.9% +$1.21M
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$104M 4.22%
5,013,764
+210,400
+4% +$4.98M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$297M
$95.4M 3.85%
4,155,670
– –
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$80M 3.23%
2,757,587
– –
KPTI icon
12
Karyopharm Therapeutics
KPTI
$44M
$79.4M 3.21%
310,888
– –
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$77M 3.11%
6,366,147
+197,800
+3% +$2.77M
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$73.2M 2.96%
6,906,158
– –
AMAG
15
DELISTED
AMAG Pharmaceuticals
AMAG
$67.6M 2.73%
3,380,506
+39,700
+1% +$904K
ALGN icon
16
Align Technology
ALGN
$12.5B
$57.8M 2.34%
147,807
-36,800
-20% -$13.6M
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$48.2M 1.95%
1,833,532
– –
CELG
18
DELISTED
Celgene Corp
CELG
$38.4M 1.55%
429,267
+34,427
+9% +$3.04M
AIMT
19
DELISTED
Aimmune Therapeutics
AIMT
$37.7M 1.52%
1,381,759
– –
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$5.06B
$35M 1.41%
1,684,180
+33,400
+2% +$525K
SHPG
21
DELISTED
Shire pic
SHPG
$34.9M 1.41%
192,738
+1,538
+0.8% +$266K
ALDR
22
DELISTED
Alder Biopharmaceuticals
ALDR
$30.9M 1.25%
1,853,101
– –
EXAS
23
DELISTED
Exact Sciences
EXAS
$24.7M 1%
313,320
– –
PRTA icon
24
Prothena Corp
PRTA
$448M
$14.4M 0.58%
1,103,325
– –
GILD icon
25
Gilead Sciences
GILD
$166B
$13.6M 0.55%
175,900
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q3 2018 Portfolio in Review

As of Q3 2018, Palo Alto Investors held 36 positions worth $2.47B, down 1.1% from $2.5B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Trading was light in Q3 2018: portfolio turnover was 0%. Palo Alto Investors opened no new positions and made no exits, leaving the 36-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q3 2018, an estimated $9.56M increase.
  • Palo Alto Investors's biggest Q3 2018 reduction was Abiomed Inc, cutting an estimated $71.5M.
  • Palo Alto Investors's ten largest holdings make up 70% of its $2.47B portfolio in Q3 2018.
  • Palo Alto Investors opened 0 new positions and closed 0 in Q3 2018.
  • Palo Alto Investors's portfolio value fell 1.1% quarter-over-quarter to $2.47B.

Based on Palo Alto Investors's 13F filing for Q3 2018, filed 14 Nov 2018.